학술논문
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
Document Type
Article
Author
Soumerai, Jacob D; Mato, Anthony R; Dogan, Ahmet; Seshan, Venkatraman E; Joffe, Erel; Flaherty, Kelsey; Carter, Jason; Hochberg, Ephraim; Barnes, Jeffrey A; Hamilton, Audrey M; Abramson, Jeremy S; Batlevi, Connie L; Matasar, Matthew J; Noy, Ariela; Owens, Colette N; Palomba, M Lia; Kumar, Anita; Takvorian, Tak; Ni, Ai; Choma, Morgan; Friedman, Chaya; Chadha, Puja; Simkins, Elizabeth; Ruiters, Jade; Sechio, Sidney; Portman, Daneal; Ramos, Lauren; Nolet, Natascha; Mahajan, Neena; Martignetti, Rosalba; Mi, Joanna; Scorsune, Krista; Lynch, Julia; McGree, Brianne; Hughes, Stephanie; Grieve, Clare; Roeker, Lindsey E; Thompson, Meghan; Johnson, P Connor; Roshal, Mikhail; Huang, Jane; Biondo, Juliana; Wu, Qun; Jacob, Allison; Abdel-Wahab, Omar; Zelenetz, Andrew D
Source
In The Lancet Haematology December 2021 8(12):e879-e890
Subject
Language
ISSN
2352-3026